Ravi Salgia, MD, PhD

Articles

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

September 2nd 2024

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Dr Salgia on Unmet Needs Associated With Treatment-Related Toxicity in Lung Cancer

October 12th 2023

Ravi Salgia, MD, PhD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting unmet needs that remain regarding treatment-related toxicities that can arise with commonly used agents in patients with lung cancer.

Dr Salgia on Clinical Gaps in the Development of Novel Targets in Lung Cancer

September 5th 2023

Ravi Salgia, MD, PhD, discusses clinical gaps in the development of novel targets in lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as potential strategies or steps to address these gaps in clinical practice.

Dr. Salgia on FDA Approval of Lorlatinib in ALK+ NSCLC

November 3rd 2018

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.

Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC

February 19th 2018

Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

Dr. Salgia on Importance of Molecular Markers in Lung Cancer

February 1st 2018

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Dr. Salgia on Next-Generation Sequencing in Lung Cancer

January 2nd 2018

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of next-generation sequencing for patients with lung cancer.